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Summary
Background: Faecal calprotectin decreases during exclusive enteral nutrition in chil‐
dren with active Crohn's disease. It is unknown how faecal calprotectin changes dur‐
ing food re‐introduction and the influence of maintenance enteral nutrition.
Aims: To study changes to faecal calprotectin during exclusive enteral nutrition and 
at food reintroduction, and explore associations with maintenance enteral nutrition.
Methods: Children with Crohn's disease were followed during exclusive enteral nutri‐
tion and during food‐reintroduction. Faecal calprotectin was measured before, at 33 
and 54 days of exclusive enteral nutrition, and at 17, 52 and 72 days after food‐rein‐
troduction. Maintenance enteral nutrition use was recorded with estimated weight 
food diaries. Data are presented with medians and Q1:Q3.
Results: Sixty‐six patients started exclusive enteral nutrition and 41 (62%) achieved 
clinical remission (weighted paediatric Crohn's disease activity index <12.5). Baseline 
faecal calprotectin (mg/kg) decreased after 4 and 8 weeks of exclusive enteral nutri‐
tion (Start: 1433 [Q1: 946, Q3: 1820] vs 33 days: 844 [314, 1438] vs 54 days: 453 
[165, 1100]; P < .001). Within 17 days of food reintroduction, faecal calprotectin in‐
creased to 953 [Q1: 519, Q3: 1611] and by 52 days to 1094 [660, 1625] (both P < .02). 
Fifteen of 41 (37%) children in remission used maintenance enteral nutrition (333 kcal 
or 18% of energy intake). At 17 days of food reintroduction, faecal calprotectin was 
lower in maintenance enteral nutrition users than non‐users (651 [Q1: 271, Q3: 1781] 
vs 1238 [749, 2102], P = .049) and correlated inversely with maintenance enteral 
nutrition volume (rho: −0.573, P = .041), kcals (rho: −0.584, P = .036) and % energy 
intake (rho: −0.649, P = .016). Maintenance enteral nutrition use was not associated 
with longer periods of remission (P = .7). Faecal calprotectin at the end of exclusive 
enteral nutrition did not predict length of remission.
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1  | INTRODUC TION
Crohn's disease (CD) is a chronic inflammatory condition which can 
affect any part of the gastrointestinal tract from mouth to anus. 
Symptoms include abdominal pain, bloody diarrhoea, weight loss, 
along with additional extra‐intestinal complications such as anaemia, 
skin rashes and arthritis.1
As Crohn's disease remains incurable, current therapy aims to 
induce and maintain clinical remission and, when possible, intestinal 
mucosal and transmural healing.2 Exclusive enteral nutrition (EEN) is 
a liquid‐only formula diet which is highly effective in achieving clini‐
cal remission in paediatric Crohn's disease.3 EEN is recommended as 
the first line treatment for active luminal Crohn's disease in children 
with up to 89% of patients achieving clinical remission when placed 
on EEN for 8 weeks.4,5 Reviews and meta‐analyses have shown that 
EEN is as effective as oral corticosteroids in inducing clinical remis‐
sion, in paediatric patients. It also has the added benefits of mucosal 
healing in a significant proportion of patients plus improvement in 
the overall nutritional status of patients.6‐9 Achieving complete mu‐
cosal healing after a course of EEN has been associated with reduced 
relapse rates and complications in the medium term.2
While the use of enteral nutrition as induction therapy of active 
Crohn's disease is well established, use of partial enteral nutrition, 
as a maintenance therapy (maintenance enteral nutrition or MEN), 
is less well studied.10 Previous research suggested that MEN may be 
effective in prolonging periods of clinical remission.11‐22 However, 
these studies have generally been of retrospective design, lacked 
robust assessment of MEN compliance and have not examined 
changes in gut markers of colonic inflammation.
We have previously described the effect that EEN has on faecal 
calprotectin, in children with active Crohn's disease during induc‐
tion treatment with EEN, which has subsequently been replicated by 
others.23,24 EEN reduces the pre‐treatment concentration of faecal 
calprotectin by an average of 48% nevertheless, less than 20%‐25% 
of those who have completed a successful course will have a mea‐
surement of FC below 250 mg/kg.24 In our previous research we 
also have described that faecal calprotectin levels increased rapidly 
in patients within 4 months of food reintroduction.23 Hence, it is 
of interest to study how quickly faecal calprotectin rises during the 
early and medium phase of food reintroduction in patients who com‐
pleted a successful course of EEN, and whether MEN use can modify 
this effect. Furthermore, the concurrent change in cytokines paral‐
leling changes in clinical and biochemical parameters has only been 
described in a few studies, contrasting with the well‐documented 
changes in patients undergoing biologic treatment.25‐28 The aim of 
the current study was to determine short and medium‐term changes 
in faecal calprotectin during food reintroduction, following induc‐
tion of remission with EEN, and to explore the effectiveness of MEN 
to influence these changes in addition to risk of subsequent clinical 
relapse.
2  | METHODS
2.1 | Patients
Patients with suspected IBD who attended the Royal Hospital for 
Children, Glasgow and neighbouring district general hospitals, were 
recruited prospectively between October 2014 and May 2017. 
Diagnosis was based on established radiological, histological and 
endoscopic guidelines.29 Disease behaviour and anatomical location 
were classified using the Paris classification.30 Patients who were 
subsequently diagnosed with Crohn's disease were followed up and 
samples were collected throughout their EEN course and during 
food re‐introduction. Patients who had already received a diagnosis 
of Crohn's disease and were undergoing a repeat course of EEN were 
also recruited. Patients who had received antibiotics in the preced‐
ing month were excluded. Written assent or consent was taken from 
participants and their carers according to good clinical practice. The 
study was approved by the NHS West of Scotland Research Ethics 
Committee (14/WS/1004) and was registered in clinicaltrials.gov 
(NCT02341248).
2.2 | Exclusive enteral nutrition and food re‐
introduction
Patients were treated for 8 weeks with a polymeric, casein‐based 
formula (Modulen IBD). Paediatric dieticians calculated the feed 
volume to provide the energy requirements for each child based 
Conclusions: The effect of exclusive enteral nutrition on faecal calprotectin is dimin‐
ished early during food reintroduction. Maintenance enteral nutrition at ~18% of en‐
ergy intake is associated with a lower faecal calprotectin at the early phase of food 
reintroduction but is ineffective in maintaining longer term remission.
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on the UK age and sex recommendations.31 Children who were un‐
dernourished (BMI Z‐score < −2 SD) were prescribed a 10% higher 
energy intake while on EEN. No other food was allowed during the 
EEN course, with the exception of black tea or coffee, water, or a 
sodium‐benzoate free carbonated sugar‐containing lemon and lime 
soft drink (7UP), clear mints and syrup flavouring. Patients were 
encouraged to consume EEN orally, however, if patients were una‐
ble to take their prescribed formula volumes within the first 3 days, 
patients were then switched to nasogastric tube feeding. While 
on EEN, patients received regular nurse and dietetic weekly sup‐
port calls and were reviewed in the clinic 4 weeks post initiation. 
If the participant did not clinically improve or deteriorated within 
the initial treatment period, EEN therapy was discontinued and 
an alternative induction treatment was commenced, usually oral 
corticosteroids.
Patients who successfully completed their course of EEN and 
entered clinical remission (defined as a decrease in weighted pae‐
diatric Crohn' wPCDAI <12.5) were encouraged to continue using 
their enteral formula as an oral supplement (MEN), consuming ap‐
proximately 20%‐25% of their total EEN volume, in addition to their 
free habitual diet. Patients had a rapid food reintroduction, with no 
specific dietary recommendations given by the members of the clini‐
cal team after the end of EEN, other than to offer MEN.
2.3 | Clinical assessment
Measurements of anthropometry were obtained and calculated as 
Z‐scores using the UK‐WHO growth charts.32 C‐reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), serum albumin and 
haemoglobin were measured at EEN initiation, end of treatment and 
at routine clinic appointments post‐EEN. Clinical disease activity was 
defined using the weighted paediatric Crohn's disease activity index 
(wPCDAI).33 Use of maintenance drug therapies were also recorded.
2.4 | Faecal calprotectin measurements
Fresh faecal samples to measure faecal calprotectin were collected 
from children at enrolment, before they began treatment with EEN. 
Two subsequent samples were scheduled to be collected during pa‐
tient's treatment with EEN at 30 and 56 days. In patients achiev‐
ing clinical remission, two further samples were collected; the first 
around 2 weeks (15 days) post‐EEN and the second around their 
2‐month (56 days) scheduled clinic review. If a sample was not col‐
lected at clinic review, patients were asked to provide a sample at 
their next time of convenience. Patients collected the whole bowel 
movement in a plastic container. The sample was collected within 
3.7 hours (Q1: 2.9, Q3: 5.0) of defecation and homogenised by me‐
chanical kneading before aliquots were stored at −70°C until further 
analysis was performed. Faecal calprotectin concentrations were 
determined using the CALPROLAB0170 (ALP) (Lysaker, Norway) 
ELISA kit according to the manufacturer's instructions and as 
described previously.34
2.5 | Cytokine profile changes during EEN
Blood samples were collected in EDTA tubes and plasma separated 
within 2 hours. The concentration of 19 inflammatory cytokines 
was analysed using the U‐PLEX Proinflam Combo 1 (IFN‐γ, IL‐10, 
IL‐12p70, IL‐13, IL‐1β, IL‐2, IL‐4, IL‐6, IL‐8, TNF‐α) (K15049K) and the 
U‐PLEX TH17 Combo (IL‐17A, IL‐17E/IL‐25, IL‐17F, IL‐21, IL‐22, IL‐23, 
IL‐27, IL‐31, IL‐33) (K15075K) assay kits (Meso Scale Discovery).
2.6 | Dietary assessment
During food re‐introduction and prior to sample collection, at 
2 weeks and 2 months post‐EEN, the energy intake of participants 
was estimated using 3‐day estimated weight food diaries. Household 
measures were used to estimate portion size. Patients were asked to 
record compliance with MEN and the exact amount consumed on 
the same food diaries. These diaries were analysed into WinDiets 10 
Software Suite (version 10; Robert Gordon University), to calculate 
energy intake.
Associations were explored between faecal calprotectin and 
both the volume and energy intake attributable to MEN. Energy 
intake was expressed in kcals, as percentage of patient's estimated 
average energy requirement (EAR) and as a percentage of energy 
intake. No MEN intake was assigned to patients who returned a food 
diary without reporting use of MEN.
2.7 | Rates of remission and relapse within 1‐year 
post EEN
Patients were followed up to a maximum of 12 months, following 
completion of EEN. Clinical relapse was defined as deterioration of 
disease requiring a further induction therapy as dictated by the clini‐
cal caring team.
2.8 | Statistics
Continuous data are displayed with median and interquartile range, 
unless otherwise stated. Differences in rates of remission based 
on disease location were evaluated using a χ2 test. Two‐sample t 
tests were performed to compare differences between two inde‐
pendent groups in patient characteristics. Mann‐Whitney U tests 
were performed to explore differences in proportional changes in 
faecal calprotectin during food reintroduction grouped together 
using various cut‐offs of faecal calprotectin at the end of EEN. Serial 
changes to faecal calprotectin during EEN were tested using a gen‐
eral linear model accounting for longitudinal measurements from 
the same subject. Post‐hoc comparisons were performed using the 
Fisher least significant difference correction. A further general lin‐
ear model, accounting for the days between sample collection, was 
performed to assess whether faecal calprotectin concentrations at 
the end of EEN could predict the subsequent rise in FC during food 
reintroduction.
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Receiver operating curves (ROC) were used to estimate the 
ability of percentage change in faecal calprotectin, during the first 
4 weeks of treatment to predict patients entering clinical remission 
by the end of EEN. Sensitivity, specificity, positive and negative pre‐
dictive values were calculated.
Kaplan‐Meier curves with Mantel‐Cox log rank test was used 
to perform survival analysis on the time to relapse based on the 
use of MEN, as taken from patient's food diaries. The same anal‐
ysis was also performed using various faecal calprotectin cut‐
offs at the end of EEN to predict the time to subsequent clinical 
relapse.
Statistical analysis was performed using Minitab version 18 sta‐
tistical software (Minitab Ltd). P‐values below .05 were considered 
statistically significant.
3  | RESULTS
3.1 | Patient population
Sixty‐eight children with Crohn's disease (25 [37%] females, median 
age 13.4 [Q1: 10.4, Q3: 14.6] years) were recruited. Six out of 68 
(9%) patients had a previous Crohn's disease diagnosis and were un‐
dergoing a second course of EEN with the remainder being newly 
diagnosed and treatment naive. Twenty‐five (37%) children had pa‐
nenteric disease; 13 (19%) presented with isolated colonic disease; 
and four (6%) had isolated ileitis. All patients presented with inflam‐
matory (B1) disease behaviour (Table 1). At treatment initiation, 
patients presented with a median BMI z‐score of −0.73 (Q1: −1.68, 
Q3: 0.21); 13 (19%) patients were classed as thin (BMI z‐score < −2) 
and, no patients were obese. Median height z‐score was −0.27 (Q1: 
−0.7, Q3: −0.43) with 5 (8%) children classed as short stature (Height 
z‐score < −2SD).
In the 53 children who completed EEN, BMI z‐scores signifi‐
cantly improved (EEN start: −0.67 [−1.52, 0.29], 54 days EEN: −0.04 
[−0.46, 0.57], P < .001) with a median weight gain of 2.4 kg (Q1: 0.83, 
Q3: 4.44) over the 8‐week course of EEN (Table S1).
Sixty‐six (97%) patients were initially treated with EEN, 
with one newly diagnosed patient starting directly on anti‐TNF 
therapy, and another with mild symptoms starting treatment 
with budesonide enemas. Of the 66 patients to start EEN, 53 
(80%) completed at least 42 days (median, 55 days; Q1: 45, Q3: 
56). Fourteen (14/66, [21%]) patients required nasogastric tube 
feeding, while the remaining 52/66 (79%) consumed EEN orally. 
Clinical remission was achieved in 41 (62%) patients (Figure 1). 
Remission on EEN was independent of disease location (P = 0.25) 
(Table S2). Of the 25 patients not to achieve remission on EEN, 
13 discontinued treatment (due to intolerance or symptom dete‐
rioration). The other 12 children completed an 8‐week course of 
EEN; of whom three achieved clinical response and the remain‐
ing nine patients did not show clinical response using wPCDAI 
definitions.
3.2 | Systemic inflammatory markers changes 
during EEN
Sixty‐three (63/66 [95%]) patients had systemic inflammatory 
markers available at treatment initiation of whom 40 (65%) had 
at least one inflammatory marker (CRP, ESR, albumin) abnormal. 
These inflammatory markers improved when patients completed 
EEN, with 12/40 (30%) having at least one marker outside the nor‐
mal range. Among those who entered clinical remission or clini‐
cally improved, and whose blood measurements were available, 
22/32 (69%) patients had all normal inflammatory makers (Table 
S1).
3.3 | Faecal calprotectin concentration changes 
during EEN
From the 66 patients who started on EEN, a faecal sample was ob‐
tained for baseline faecal calprotectin measurement in 53 (80%). 
Median faecal calprotectin at the start of treatment was 1433 mg/
TA B L E  1   Baseline demographics and phenotypic characteristics 
of the 66 Crohn's disease patients treated with exclusive enteral 
nutrition
 N (%)
Males (%) 42 (64)
Newly diagnosed (%) 60 (91)
Age (y) 13.4 (10.7, 14.9)
Age at diagnosis (%)
A1a (0 to <10) 14 (21.2)
A1b (10 to <17) 50 (75.8)
A2 (17 to <40) 2 (3)
Disease location (%)
L1, B1 4 (6)
L1, L4a, B1 2 (3)
L2, B1 11 (17)
L2, L4a, B1 10 (15)
L2, L4a, L4b, B1 3 (5)
L3, B1 9 (14)
L3, L4a, B1 10 (15)
L3, L4a, L4b, B1 14 (21)
L3, L4b, B1 2 (3)
L4a, B1 1 (2)
Perianal 6 (9)
Disease behaviour (%)
B1 66 (100)
B2 0
B2 0
B2B3 0
Note: Paris disease classification.
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kg [Q1: 947, Q3: 1820] with 52/53 having a raised faecal calprotectin 
(>50 mg/kg), and 50 (94%) having a value >250 mg/kg.
During EEN, a sample was collected at a median of 33 days (Q1: 
36, Q3: 39), by which time faecal calprotectin concentrations had 
decreased by a median of 597 mg/kg from baseline values (33 days 
EEN concentration: 836 mg/kg [Q1: 296, Q3: 1303], P < .001; % 
decrease from baseline: 33% [−17.9, 76.2]). As patients completed 
EEN, a sample was collected at a median of 54 days (53, 56) on 
treatment. The reduction in faecal calprotectin continued during 
the second half of treatment and reached a median of 453 mg/
kg (165, 1100; P < 0.001) compared with EEN start by the end of 
EEN; decreasing by a median of 59% (−3.2, 88.7) from their baseline 
value.
There was no difference in baseline faecal calprotectin levels 
between patients who achieved remission on EEN and those who 
did not (remission group, median 1447 mg/kg [855, 1839] vs non‐re‐
mission median 1684 mg/kg [1233, 1857]; P = .67). In patients who 
completed 8 weeks of EEN, there was no difference in faecal calpro‐
tectin at the end of EEN between patients achieving remission and 
those that did not (remission group FC: N = 29, 430 mg/kg [Q1: 141, 
Q3: 1047], no remission group FC: N = 8, 911 mg/kg [Q1: 370, Q3: 
1791], P = .121). When performed without the requirement of com‐
pleting EEN and instead using the patients ‘exit’ sample i.e. including 
samples that may be collected at 4wk EEN if the patient discontin‐
ued at this point then there is a significant difference in FC between 
remission vs no remission (remission: n = 35 median: 451 [133, 1068] 
vs no‐remission: n = 12 median: 1331 [497, 1596], P value = 0.04).
Patients who entered clinical remission by the end of EEN had a 
greater reduction in faecal calprotectin by the midpoint of EEN than 
those who did not achieve remission (remission group FC change: 
689 mg/kg [246, 1127]; non‐remission group FC change: 182 mg/kg 
[−144, 548]; P = 0.007) (Table S1).
Patients who completed EEN without achieving remission did 
not have a significant decrease in faecal calprotectin by the end of 
treatment (EEN start: 1322 [1148, 1699], 54 days EEN: 1233 [265, 
1732], P = .35).
Using ROC curve analysis, a percentage reduction in faecal 
calprotectin during the first 4 weeks of EEN resulted in an AUC of 
0.75 (CI: 0.59‐0.92) and it was found that a reduction of greater 
than 45% from baseline concentrations produced a sensitivity of 
100%, a 57.7% specificity and a positive and negative predictive 
validity of 100% and 38.9% of detecting patients who achieved 
remission at the end of EEN, respectively (Table 2). Similar ROC 
curve analysis was performed using changes in anthropome‐
try, specifically the change in weight (kg), % weight change (kg), 
weight z‐score, during the same time period. These models 
returned AUC of 0.79 (CI: 0.65‐0.9); 0.76 (CI: 0.61‐0.9); 0.75 
(CI: 0.57‐0.93) respectively.
Using an increase in weight z‐score of > 0.21 points during 
this time produced a sensitivity and specificity of 100% and 59% 
F I G U R E  1   Schematic flowchart of patients recruited to study with treatment outcomes during EEN (response defined by weighted 
paediatric Crohn's disease activity index). Abbreviations: EEN, exclusive enteral nutrition
Study Recruitment
Enrolled into study
Other induction treatment
2
68
Started EEN
Discontinued EEN
Remission on EEN (wPCDAI < 12.5) Responder (wPCDAI change < 17.5) Completed, non-responder
9
13
Completed EEN course
66
53
EEN Responder
44
341
29 12
MEN No-MEN
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respectively, and with a positive predictive validity of 100% and neg‐
ative predictive validity of 40%.
3.4 | Cytokine profile changes during EEN
Prior to EEN initiation, no differences in cytokine concentration 
were observed between responders and non‐responders. Using 
paired analysis, patients who entered clinical remission had a signifi‐
cant decrease in the concentration of IL‐6, IL‐17E, IL‐17F and IL‐31 
(P < .05), (Table S3). Combining measurements from the start of EEN 
and end of EEN there were significant positive correlations found 
between FC and IFN‐y, IL‐1β, IL‐6, IL‐8, IL‐17a, IL‐17F, IL‐22, IL‐23, 
IL‐27, IL‐31 and IL‐33 in patients who achieved clinical remission, 
(Table S3). There was no change to cytokine levels in patients who 
did not achieve clinical remission.
3.5 | FC changes during the early food 
reintroduction phase
A faecal sample was obtained at a median of 17 days (14, 21) post‐
EEN in 23 patients of those who achieved remission to study changes 
in FC in the early food reintroduction phase. Within this early food 
TA B L E  2   Prediction of clinical remission by 8 wk EEN, using % FC decrease from baseline to 4 wk EEN
% 0 to 4 wk FC 
decrease
Sensitivity  
(%) 95% CI
Specificity  
(%) 95% CI
Likelihood  
ratio PPV (%) NPV (%)
>19.2 42.9 9.9‐81.6 69.2 48.2‐85.7 1.39 81.8 27.3
>24.2 57.1 18.4‐90.1 69.2 48.2‐85.7 1.86 85.7 33.3
>29.3 71.4 29.0‐96.3 69.2 48.2‐85.7 2.32 90 38.5
>33.2 71.4 29.0‐96.3 65.4 44.3‐82.8 2.06 89.5 35.7
>34.0 71.4 29.0‐96.3 61.5 40.6‐79.8 1.86 88.9 33.3
>37.9 71.4 29.0‐96.3 57.7 36.9‐76.7 1.69 88.2 31.3
>41.9 85.7 42.1‐99.6 57.7 36.9‐76.7 2.03 93.8 35.3
>45.0 100 59.0‐100.0 57.7 36.9‐76.7 2.36 100 38.9
Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
Optimal cut‐off is donated in bold.
F I G U R E  2   Faecal calprotectin 
concentrations during a course of EEN and 
at food reintroduction in patients entering 
clinical remission on EEN. Comparisons 
made between EEN start vs EEN End, 
and from EEN End till food reintroduction 
period; connecting lines indicating 
paired sample; reference line added at 
250 mg/kg, indicating raised FC. P for 
Fisher pairwise comparisons following 
general linear model. Abbreviations: EEN, 
exclusive enteral nutrition
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reintroduction period, faecal calprotectin had significantly increased 
by 91% (2, 486) from their EEN cessation levels (54 days EEN: 
430 mg/kg [141, 1047] vs 17 days post EEN 953 mg/kg [519, 1611]; 
P = .025) corresponding to a median daily rate of faecal calprotectin 
increase of 20 mg/kg/d (3.5, 50).
A second faecal calprotectin sample was collected at their first 
scheduled clinic review appointment. Due to the substantial vari‐
ation in the timing these appointments took place at, participants 
and their associated collected samples (min: 30 days, max: 115 days) 
were divided into two groups; a medium‐term food (52 days [51, 
57]); and a long‐term (72 days [65, 83]) food reintroduction phase. 
In the 20 patients whose samples were collected during the medium 
phase of food re‐introduction, faecal calprotectin concentration in‐
creased by 327 mg/kg (−295, 1345) compared with their end of EEN 
levels (52 days FC post EEN: 1094 mg/kg [660, 1625]; vs end of EEN: 
430 mg/kg [141, 1047], P = .003). There was no difference in day 52 
levels compared to baseline (pre‐EEN) (52 days FC: 1094 mg/kg [660, 
1625] vs baseline FC: 1433 mg/kg [947, 1820], P = .124) (Figure 2). 
A faecal calprotectin sample was obtained from 19 other patients 
whose first post‐EEN clinic appointment was at a median of 72 days 
(65, 83) of food reintroduction. In these patients, faecal calprotec‐
tin had increased significantly from the end of EEN values (EEN end 
FC: 430 mg/kg [141, 1047] vs 72 days FC: 1159 mg/kg [676, 1293]; 
P < .001). However, there was no difference when compared to the 
early food reintroduction (P = 0.25) or medium food reintroduction 
(P = 0.19) (Figure 2). The increase in faecal calprotectin during food 
re‐introduction preceded changes to other disease activity mark‐
ers (including wPCDAI, ESR and albumin) which remained similar to 
values at the end of EEN (Table S1).
3.6 | MEN and changes in FC during food 
reintroduction
From the 41 patients who entered clinical remission, 29/42 (69%) 
were prescribed MEN upon EEN completion. The median pre‐
scribed volume of MEN was 400 mL (Q1: 262, Q3: 400), with a 
median prescribed energy intake of 450 Kcal/d (Q1: 323, Q3: 600) 
or 20% (15, 25) of patients daily EAR. Of the 37 food diaries re‐
turned, 15 (41%) recorded use of MEN. Patients who recorded use 
of MEN consumed a median of 333 Kcal [Q1: 330, Q3: 438] receiv‐
ing 18% [Q1: 16.2, Q3: 24.7] of their recorded total energy intake 
(Table S4). Regardless of amount of MEN consumed, patients who 
recorded use of MEN during the early period of food reintroduction 
had significantly lower FC compared to those not using MEN (MEN 
users FC: 651 [271, 1781] vs non‐MEN users FC: 1238 [749, 2102], 
P = .049) (Figure 3).
In the same, early phase of food reintroduction, there was an 
inverse correlation between faecal calprotectin and MEN when ex‐
pressed as volume (mL), calorific content (Kcal), % MEN contributed 
to TEI and % MEN contributed to patients EAR (MEN volume rho: 
−0.573, P = .041; MEN Kcal rho: −0.584, P = .036; MEN % TEI rho: 
−0.649, P = .016; MEN % EAR rho: −0.614, P = .026) (Figure S2). This 
effect was lost during the medium‐ and long‐term periods of food 
reintroduction.
3.7 | Relapse rates at 1‐year post EEN
Twelve of the 41 (29%) patients who entered clinical remission on 
EEN, remained in remission 12 months post EEN. The median length 
of remission in patients who subsequently relapsed following com‐
pletion of EEN was 207 days (Q1: 108, Q3: 328).
Survival analysis of MEN use, assessed either as prescribed by 
the clinical dietetic team, or according to their reported use on di‐
etary records, was not associated with prolongation of length of re‐
mission (prescribed MEN group: 184 days [Q1: 103, Q3: 322] vs non 
prescribed MEN group: 257 days [167, 350]; P = .44; recorded MEN 
use: 181 days [71, 341] vs recorded non‐MEN use: 208 days [141, 
212]; P = .70) (Figure S3). There was no difference in relapse rates at 
either 6 months (recorded MEN: 5/9 [56%] vs recorded non‐MEN: 
10/32 [31%]; P = .18) or 12 months (recorded MEN: 8/9 [89%] vs 
recorded non‐MEN: 21/32 [66%]; P = .18) post‐EEN.
A faecal calprotectin cut‐off <100, <250 and <500 mg/kg was 
used in an attempt to explore the predictive ability of faecal calpro‐
tectin at the end of EEN with an increase in faecal calprotectin during 
food reintroduction. There was no difference in the subsequent rise 
in faecal calprotectin concentration during the early food reintro‐
duction when using <100 mg/kg or <250 mg/kg as cut‐offs (FC<100 
absolute change: 1158 [Q1: 612, Q3: 1615] vs FC >100 absolute 
change: 245 [−76, 699], P = .14; FC <250 absolute change: 612 [196, 
1158] vs FC >250 absolute change: 245 [−157, 699], P = .23). Patients 
with a faecal calprotectin <500 mg/kg had a greater increase in fae‐
cal calprotectin both in absolute concentration and proportionally 
during early food reintroduction (FC <500 absolute change: 581 
[182, 1206] vs FC >500 absolute change: 31 [−184, 284], P = .004; 
FC <500% change: 316 [81, 665] vs FC >500% change: 0.01 [−17, 
27], P = .007).
During the medium food reintroduction, patients with faecal cal‐
protectin <250 mg/kg and <500 mg/kg at the end of EEN had greater 
increases in faecal calprotectin both in absolute concentration (FC 
F I G U R E  3   Faecal calprotectin concentrations during the early 
(17 d) food reintroduction period, grouping based on self‐reported 
MEN use. Dots representing individual values, line showing median 
and IQR. Abbreviations: MEN, Maintenance enteral nutrition
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<250 absolute change: 1146 [82, 1620], vs FC >250 absolute change: 
133 [−1117, 806], P = .04; FC <500: 1107 [82, 1466] vs FC >500: 
−281 [−1185, 394], P = .013) and proportionally (FC <250% change: 
1024% [408, 21 521], vs FC >250% change: 20.8% [−61.4, 78.8], 
P = .008; FC <500% change: 541% [40, 3350] vs FC >500% change: 
−23.3% [−61.4, 25.8], P = .017). There was a similar increase, both in 
absolute concentration and proportional change in faecal calprotec‐
tin, when <100 mg/kg was used to stratify patients (FC <100:763 
[24, 1571] vs FC >100:260 [−727, 1107], P = .29; FC<100:4787 [131, 
46518] vs FC>100:26 [−56, 516], P = .08).
Performing survival analysis using the concentration of faecal 
calprotectin at the end of EEN, neither a FC <250 mg/kg nor a FC 
<500 mg/kg value was associated with a longer time to subsequent 
clinical relapse (FC <250 remission length: 208 [145, 252] days, FC 
>250 remission length: 201 [107, 341] days; P = .41; FC <500 re‐
mission length: 230 [124, 320] days vs FC >500 remission length: 
181 [108, 334] days; P = .59). When using the stricter cut‐off of FC 
<100 mg/kg at the end of EEN, there was a trend for patients to have 
longer periods of remission (FC <100 remission length: 382 days 
[215, 500] vs FC >100 remission length: 207 days [108, 334]; P = 
0.07) (Figure 4).
3.8 | Effect of other maintenance treatments
At the end of EEN (24/41, 59%), patients had begun the use of aza‐
thioprine as maintenance therapy. Rates of azathioprine use was 
similar between MEN and non‐MEN users (P = .17). Use of azathio‐
prine at last follow‐up during food reintroduction was not associated 
with a significant increased remission length (Time to relapse, MEN 
users: 224 days [143, 334] days vs non‐MEN users: 180 days [78.5, 
311], P = .51).
4  | DISCUSSION
EEN continues to be the only established dietary treatment to in‐
duce remission in active paediatric Crohn's disease.3 It has the 
added benefit over corticosteroids of improving nutritional status 
and has higher rates of mucosal healing. The results of this study 
reflect those published in the literature, with the largest decrease in 
FC occurring within the first 4 weeks of treatment, and a slower yet 
persistent decrease during the second half of treatment.8,23
The observed decrease in inflammatory cytokine expression 
is consistent with the published literature and reflects a reduc‐
tion in systemic inflammation in patients responding to EEN in 
parallel with clinical activity improvement and reduction in faecal 
calprotectin.25
While, there was no difference in the levels of faecal calpro‐
tectin between patients achieving remission and those remaining 
with active disease at the end of EEN, this is in part due to the large 
interindividual faecal calprotectin response during EEN; as well as 
the faecal calprotectin remaining raised (>250 mg/kg) in 19/29 (66%) 
patients entering clinical remission at 8 weeks of EEN. Similar to 
treatment with corticosteroids, the levels of faecal calprotectin re‐
main high in most patients who complete EEN, with this prospective 
study showing raised faecal calprotectin values indicative of ongoing 
colonic inflammation.8,23,35‐37
It has also been shown that faecal calprotectin reverts to pre‐
treatment levels within 4 months post‐EEN, and that up to 55% of 
patients in clinical remission can have a raised faecal calprotec‐
tin.23,38 Complementing this previous work, this more detailed study 
demonstrated that the rise in FC post EEN to pre‐treatment levels 
occurs more rapidly than previously recognised.23 We show that a 
significant rise in faecal calprotectin is apparent within just 17 days 
of food reintroduction in the majority of patients and had reverted 
to pre‐treatment levels within 52 days of EEN cessation, despite 
concomitant maintenance treatment with azathioprine and/or MEN 
in most patients. This highlights the potent role of early dietary in‐
flammatory triggers within the early food reintroduction phase in 
the post‐EEN period; as well as suggesting the maintenance thera‐
pies used are inadequate in preventing the development of subclini‐
cal inflammation following EEN.
The evidence to support the benefit of MEN to prolong remis‐
sion following a successful course of EEN is at present inconsistent. 
The current study adds to the existing evidence by showing that 
MEN may delay the immediate rise of faecal calprotectin, during 
early food reintroduction; but this effect is only short‐lived and is 
probably at least partly dependent on the volume and calorific con‐
tent of MEN consumed. This short‐term effect is likely to be due to 
displacement of part of the habitual diet by consuming MEN.39
F I G U R E  4   Kaplan‐Meier survival analysis using various cut‐offs in FC at the end of EEN to stratify patients with their time to subsequent 
relapse, censored at 1 y. FC, faecal calprotectin; EEN, Exclusive enteral nutrition.
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The lack of short and long‐term compliance on MEN as reported 
in this study also highlights adherence challenges that patients with 
CD face and perhaps taste fatigue with MEN. There are many con‐
flicting reports on the utility of MEN as a maintenance therapy. We 
have previously published a retrospective analysis showing up to 
50% of patients who used MEN as their sole maintenance therapy 
remained in remission within a 1‐year follow‐up.11 This was similar to 
the response obtained in patients using azathioprine (azathioprine 
alone: 65%; azathioprine and MEN combined: 67%), and significantly 
better than those using no maintenance therapy (15%).
While the results from this earlier study suggested that MEN 
may be as effective as azathioprine in maintaining remission, it did 
not have a robust marker of compliance to MEN, as the current study 
did, making it difficult to assess patient's continued compliance 
during the length of the study, nor did it assess gut inflammation, 
as this study did. In this study using more detailed analysis, using 
patients’ recorded MEN use as well as measuring faecal calprotectin, 
we failed to replicate these previous results.
Another retrospective study, in which MEN was provided at 30% 
of EAR, also did not find the use of MEN to be associated with longer 
periods of remission, with 78% of patients who used MEN and 77% 
of patients who remained on habitual diet relapsing within 1 year.18 
Of note however, EEN followed by MEN did have improved remis‐
sion rates in the short term (6 months) and some of the patients in 
the study received MEN after a course of steroids rather than EEN.
The most compelling evidence to date for the use of MEN 
remains two RCTs in adults in Japan.40,41 The first study compared 
MEN use against patients following their free habitual diet. The au‐
thors found MEN to be associated with a lower incidence of clinical 
relapse during one year of follow‐up.40 However, this study differs 
from this and previous reports as authors delivered MEN using 
elemental formula via nasogastric tube feeding, at 50% of patient's 
daily energy intake, at least twice as much as the current study. More 
recently, a second group from Japan have shown MEN at 50% using 
elemental formula to be as effective as 6‐mercaptopurine, in main‐
taining remission in a cohort of adult IBD patients in an RCT with 
a 2‐year follow‐up.41
Other groups have also reported on the clinical efficacy of MEN 
when recommended at high volumes of ~50% EAR.42‐44 These ob‐
servations in conjunction with the association we observed between 
the amount of consumed MEN and faecal calprotectin levels further 
support our hypothesis for a “dose‐response” association between 
MEN and disease relapse with the current study “under‐dosing” pa‐
tients hence not demonstrating medium to long‐term clinical effect.
However, not all studies giving high dosage of MEN found pro‐
longed length of remission. Knight et al (2005) gave patients with 
1 L/d of MEN but without demonstrating a clinical benefit. However, 
the authors of this study did not formally record patient's compli‐
ance to MEN and felt this may have been a significant confounding 
factor with interpreting the results.19
The heterogeneity between studies and lack of a prospective 
RCT study in children remains a significant limitation in this area. 
While our study is not an RCT, we have attempted to prospectively 
study the effect of MEN while at the same time assessing its com‐
pliance with self‐reported weighted food diaries, a caveat not often 
captured within the existing literature.11,18,45,46 With only half of the 
patients returning a food diary in which to assess MEN compliance 
this remains a limitation in our study but is useful to highlight many 
patients who are “prescribed” MEN do not actually take it, suggest‐
ing that better reinforcement from the treating team may help im‐
prove compliance.
As the beneficial effects of MEN in our study are associated 
with a reduced faecal calprotectin during the early period of food 
reintroduction only, when compliance is likely to remain highest, 
it remains unclear at present whether MEN can be used as a truly 
effective maintenance therapy in the longer term. This raises the 
question of developing other adjuvant dietary treatments with 
better tolerance and adherence profiles for long‐term dietary 
management of Crohn's disease.47 This has been supported by a 
recent study demonstrating patients prefer dietary advice rather 
than MEN after treatment with EEN.48 Such treatments can be 
used in isolation, interchangeably, or preferably in conjunction 
with MEN.
The mechanism of action for EEN, as with MEN, remains to 
be fully clarified, though several studies have implicated the im‐
portance of the gut microbiome.49‐52 To our knowledge there is 
only one study exploring the influence of MEN on the microbiome. 
However, as this was carried out in only two patients, with vary‐
ing sample time‐points, it is difficult to place these results in the 
larger context, due to the inherent heterogeneity between sub‐
ject's microbiome.49
Our data on clinical response to treatment are similar to pre‐
vious reports but while patient's weight increased too, the mag‐
nitude of this effect was not as large as published historically.5,53 
This may be explained in part by our patients not having as low 
z‐scores suggesting improved detection and earlier diagnosis. The 
weight gain we observed in this study is similar  to other published 
literature.5,44 We have demonstrated that changes in patient's 
weight during the first 4 weeks of treatment with EEN predicted 
which patients would enter clinical remission by the end of EEN. 
While this is very similar to the prediction validity using changes 
in faecal calprotectin during the same period, using weight change 
as a predictor creates a circular argument with assessing disease 
 improvement using wPCDAI. We were unable to perform this 
analysis using changes in systemic markers of inflammation (CRP, 
ESR, inflammatory cytokines) as it is not the practice in our centre 
to routinely venepuncture patients at the midpoint of EEN, who 
are responding well clinically.
In conclusion, the current study confirms previous observa‐
tions that EEN is a successful treatment in Crohn's disease induc‐
ing clinical remission and reducing FC. Exacerbation of subclinical 
inflammation is rapid and occurs soon after food reintroduction with 
MEN demonstrating a modest modifying effect only in the first few 
weeks. Future research should explore dietary triggers of Crohn's 
disease relapse during the food‐reintroduction phase and their inter‐
play with the gut microbiome. The dose‐response signal identified 
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in this study should be ascertained formally within well‐designed 
dose‐response studies.
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